DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Kowanetz M. et al.
Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients.
WCLC; 2016 abstr. OA20.01
Access:
We do not assume any responsibility for the contents of the web pages of other providers.